The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...

The medical supply company is leaning on its plants in Canada, China, Ireland, and the U.K. to shore up reserves hurt by flooding of its North Carolina plant.

Analyst David Larsen from BTIG maintained a Buy rating on LifeMD (LFMD – Research Report) and keeping the price target at $12.00. David ...